Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
Company profile
Ticker
ODYY
Exchange
Website
CEO
Joseph Michael Redmond
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
Former names
Odyssey Group International, Inc.
SEC CIK
ODYY stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
13 Jan 23
8-K
Departure of Directors or Certain Officers
6 Jan 23
8-K
Entry into a Material Definitive Agreement
3 Jan 23
10-Q
2023 Q1
Quarterly report
14 Dec 22
DEF 14A
Definitive proxy
29 Nov 22
8-K
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
25 Nov 22
8-K
Other Events
23 Nov 22
8-K
Entry into a Material Definitive Agreement
23 Nov 22
PRE 14A
Preliminary proxy
18 Nov 22
8-K
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
4 Nov 22
Latest ownership filings
Financial summary
| Quarter (USD) | Oct 22 | Jul 22 | Apr 22 | Jan 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Jul 22 | Jul 21 | Jul 20 | Jul 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 50.50 k | 50.50 k | 50.50 k | 50.50 k | 50.50 k | 50.50 k |
| Cash burn (monthly) | 7.35 k | 35.05 k | 692.60 k | 729.58 k | 94.90 k | 191.27 k |
| Cash used (since last report) | 21.12 k | 100.79 k | 1.99 mm | 2.10 mm | 272.87 k | 549.96 k |
| Cash remaining | 29.38 k | -50.29 k | -1.94 mm | -2.05 mm | -222.37 k | -499.46 k |
| Runway (months of cash) | 4.0 | -1.4 | -2.8 | -2.8 | -2.3 | -2.6 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Jan 23 | John P Gandolfo | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 500,000 | 150.00 k | 1,500,000 |
| 12 Jan 23 | Christine Farrell | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 400,000 | 120.00 k | 1,700,000 |
| 12 Jan 23 | Christine Farrell | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 100,000 | 30.00 k | 1,300,000 |
| 12 Jan 23 | Jerome H Casey | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 500,000 | 150.00 k | 1,500,000 |
| 12 Jan 23 | Ricky Richardson | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 500,000 | 150.00 k | 1,000,000 |
| 12 Jan 23 | J Michael Redmond | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 400,000 | 120.00 k | 3,500,000 |
| 12 Jan 23 | J Michael Redmond | RSU ODYY - Common Stock | Grant | Acquire A | No | No | 0.3 | 100,000 | 30.00 k | 3,100,000 |
Press releases
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
19 Dec 22
Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
23 Nov 22
Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
3 Nov 22
Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
1 Nov 22